Currently, the dual combination of checkpoint inhibitors is being evaluated in various phase II clinical trials for metastatic CRC patients, for example, durvalumab, an anti-PD-L1 mAb, and tremelimumab, an anti-CTLA-4 mAb (NCT03101475). This evidence concerns the gene CD274 and colorectal carcinoma.